Title
FDA Act of 2009: Strengthening health product regulation
Law
Republic Act No. 9711
Decision Date
Aug 18, 2009
The FDA Act of 2009 establishes the Food and Drug Administration in the Philippines to regulate health products, ensure compliance, and protect the health of the Filipino people.

Law Summary

Policy Declaration

  • The State declares its policy to protect and promote public health through effective regulation of health products.
  • Emphasizes enhancing regulatory capacity for inspection, licensing, and monitoring of establishments and health products.

Objectives of the Act

  • Enhance and strengthen the FDA's administrative and technical capacities.
  • Ensure comprehensive monitoring and regulation of establishments and products.
  • Provide coherence in regulatory systems covering establishments and products.

Functions, Powers, and Duties of the FDA

  • Administer and enforce the Act and its rules.
  • Primary jurisdiction over sampling health products.
  • Analyze and inspect health products.
  • Establish standards for health product identity, purity, safety, efficacy, quality, and packaging.
  • Issue certificates of technical compliance and conduct spot-check inspections.
  • Conduct product testing before authorization to ensure safety and efficacy.
  • Require reporting of incidents indicating harm caused by health products.
  • Issue cease and desist orders; ban, recall, or withdraw harmful products after due process.
  • Strengthen post-market surveillance and monitor adverse events.
  • Develop standards and authorize establishments and products.
  • Oversee research studies related to health product safety.
  • Regulate advertising and marketing related to health products.
  • Maintain bonded warehouses for confiscated goods.
  • Exercise additional powers as necessary to fulfill its mandate.

Organizational Structure of the FDA

  • Establishment of four major Centers categorized by product: Drug, Food, Cosmetics, Device/Radiation Health.
  • Each Center includes divisions for Licensing and Registration, Product Research and Standards Development, and Laboratory Support.
  • Additional offices: Administration and Finance Office, Policy and Planning Office, Field Regulatory Operations Office, and Legal Services Support Center.

Leadership and Appointment

  • FDA headed by a Director-General (undersecretary rank) appointed by the President.
  • Assisted by two Deputy Directors-General for Administration/Finance and Field Regulatory Operations.
  • Qualifications for leadership roles include relevant degrees, management experience, and disclosures to prevent conflicts of interest.
  • Directors of Centers and Field Offices appointed by the Secretary of Health.

Staffing and Staffing Pattern

  • FDA reviews staffing and position titles subject to Secretary of Health approval.

Key Definitions

  • Comprehensive definitions covering terms like FDA, food, drug, device (medical, radiation, health-related), cosmetics, labeling, manufacturer, distributor, retailer, veterinary drugs, household hazardous substances, licensing, registration, misbranding, and health products in general.

Prohibited Acts

  • Manufacture, import, export, sale, distribution, or promotion of adulterated, unregistered, or misbranded health products.
  • Prohibiting false guarantees and alterations affecting product labeling.
  • Operating without the required FDA license.
  • Selling health products beyond expiry.

Penalties for Violations

  • Imprisonment from 1 to 10 years and fines ranging from P50,000 to P500,000, increased for manufacturers/importers/distributors.
  • Additional fines for continuing violations.
  • Penalties extend to responsible corporate officers.
  • Deportation for foreign nationals who violate the Act.

Administrative Procedures

  • FDA conducts hearings on violations.
  • Opportunities for parties to be heard before FDA decisions.
  • Both criminal and administrative actions may be pursued independently.

Administrative Sanctions

  • Cancellation or suspension of FDA authorizations.
  • Fines from P50,000 to P500,000 with additional fines for ongoing violations.
  • Product destruction and establishment closure.

Additional Powers of the Director-General

  • Hold persons in contempt for disregarding FDA orders.
  • Administer oaths, issue subpoenas for investigations.
  • Acquire information from government units.
  • Issue seizure orders for violative articles pending hearings.
  • Deputize law enforcement agencies for implementation.

Appeal Processes

  • FDA decisions are final and executory after 15 days unless an administrative appeal is filed.
  • Appeals may be made to the Secretary of Health upon filing notice and bond.
  • Appeals do not automatically stay FDA decisions unless ordered.

Fee Structure and Income Retention

  • Annual fees determined and reviewed by the FDA with Secretary approval.
  • Extra regulatory fees include fines, penalties, and service charges.
  • FDA authorized to retain income as a special regulatory fund used primarily for infrastructure, human resources, equipment, and maintenance.
  • Fund can accept grants and donations; cannot be reallocated without COA rules.
  • Legal fund established from interest for defending FDA officials/employees.

Regulatory Enforcement Unit (REU)

  • Established for five years to enforce FDA regulations at the regional level with armed, uniformed personnel.
  • REU officers serve and execute FDA orders and warrants.
  • Unit led by lawyer Division Director and assistant.
  • Law enforcement authority limited to FDA regulatory functions.

Testing Laboratories and Field Offices

  • Establish at least one testing laboratory each in Luzon, Visayas, and Mindanao with state-of-the-art equipment.
  • Existing labs in Cebu and Davao upgraded; new lab in Subic established.
  • Authority to accredit and call on other government/private labs for testing.
  • FDA field offices established nationwide, bringing regional food and drug officers under the FDA.
  • Field offices composed of licensing/inspection, satellite labs, and administrative divisions.

Expansion and Organizational Units

  • FDA may create new units as necessary to meet emerging health concerns and international standards.
  • Additional plantilla positions may be created subject to existing rules.

Appropriations and Budget

  • Existing DOH budget for BFAD and BHDT used for implementation.
  • FDA income may augment appropriations.
  • Subsequent funding included in General Appropriations Act.

Implementing Rules and Regulations

  • DOH to promulgate implementing rules within 120 days after enactment.

Congressional Oversight

  • Oversight Committee formed with members from relevant Congressional committees to monitor FDA implementation and income use for five years.

Transitory Provisions

  • Current BFAD and BHDT officials and employees transferred to FDA with no loss of rank or benefits.
  • All assets, powers, functions, and funds transferred accordingly.

Coverage and Exclusive Jurisdiction

  • Act governs all health products but does not affect exclusive jurisdiction of other specialized agencies and laws in specific areas.

Separability Clause

  • Invalidity of any provision does not affect the remainder of the Act.

Repealing and Effectivity Clauses

  • Laws and issuances inconsistent with the Act are repealed or amended.
  • Act takes effect 15 days after publication in the Official Gazette or two newspapers of general circulation.

Analyze Cases Smarter, Faster
Jur helps you analyze cases smarter to comprehend faster—building context before diving into full texts.